ClinicaliQ Trial Snapshot
- A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours — Recruiting • Phase I • Oncology • NCT06977737.
- ATTR-01 is the experimental drug being studied in the ATTEST clinical trial. The drug is made from a common cold virus that has been changed to only infect and multiply in cancer cells. This virus delivers an immune therapy drug into the….
- Sponsor: Accession Therapeutics Limited.
Verify eligibility, endpoints and current status on the original source registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
ATTR-01 is the experimental drug being studied in the ATTEST clinical trial. The drug is made from a common cold virus that has been changed to only infect and multiply in cancer cells. This virus delivers an immune therapy drug into the cancer that is intended to promote a participant's own immune system to attack the cancer. The first part of this trial (sub-protocol A) is a phase 1 trial including dose escalation and expansion at one or more doses. It is the first time that ATTR-01 will be given…
Eligibility Snapshot
- : * Consenting male and female adults (18 years of age) with select solid epithelial tumour indications known to have high frequency (75 percent) of αvβ6 integrin receptor expression as detailed in the applicable SP. * Received and failed/intolerant of Standard of Care (SoC) therapy where eligible (not including neoadjuvant). * Tumour lesion (not previously irradiated), suitable for safe pre- and post-treatment biopsies. * Measurable disease by Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1. * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1. * Minimum life expectancy anticipated to be greater than three months * Willing to undertake appropriate measures of hygiene to prevent any spread of virus and protection of vulnerable individuals. * Adequate organ function. * Compliant with requirements for prior treatment washout and contraceptive measures applicable to genetically modified organisms (GMOs) and cancer therapies * Prior immune checkpoint antibody therapies as single agents or in combination with other anti-cancer agents is permissible.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.